#### 1 Pre-COVID-19 ex vivo cross-reactive IFN-γ cellular response to SARS-CoV-2 spike

# 2 overlapping peptides is more robust among Kenyan compared to Swedish adults

- **3 Running Title**: Pre-COVID-19 cross-reactive IFN-γ responses to SARS-CoV-2 spike:
- 4 Kenyan vs. Swedish adults

#### 5 Authors

- 6 Perpetual Wanjiku<sup>1</sup>\*, Benedict Orindi<sup>1</sup>, Jedidah Mwacharo<sup>1</sup>, James Chemweno<sup>1</sup>, Henry
- 7 Karanja<sup>1</sup>, Barbara Kronsteiner<sup>2,3</sup> Oscar Kai<sup>1</sup>, Daniel Wright<sup>4</sup>, Lynette Isabella Ochola-
- 8 Oyier<sup>1,5</sup>, Christopher Sundling<sup>6,7</sup>, Susanna Dunachie<sup>2,3</sup>, George M Warimwe<sup>1,5</sup>, Anna
- 9 Färnert<sup>6,7</sup>, Philip Bejon<sup>1,8</sup>, Francis M. Ndungu<sup>1,5,6†</sup>, Eunice Nduati<sup>1,5†</sup>.

### 10 Affiliations

- Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya
   Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
   Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Thailand
   Department of Pediatrics, University of Oxford, Oxford, United Kingdom
   Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
- 18 University of Oxford, Oxford, United Kingdom
- Division of Infectious Diseases, Department of Medicine Solna, and Center for
   Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
- Department of Infectious Diseases, Karolinska University Hospital, Stockholm,
   Sweden
- 8. Modernising Medical Microbiology, Nuffield Department of Medicine, University of
   Oxford, Oxford, United Kingdom
- 25 \* Correspondence to: <a href="mailto:pwanjiku@kemri-wellcome.org">pwanjiku@kemri-wellcome.org</a>
- 26 *†*These authors contributed equally.

## 27 Highlights

- Higher frequencies of cross-reactive IFN-γ-secreting cells among Kenyan pre COVID-19 adults compared to Sweden.
- Trends of higher TNF- $\alpha$  and IFN- $\gamma$  T-cell responses among Kenyan adults.
- Presence of pre-existing T-cell immunity in Sub-Saharan Africa.

#### 32 Abstract

# 33 Introduction

- 34 Global WHO data indicate that Sub-Saharan African (SSA) countries, such as Kenya,
- 35 experienced reduced coronavirus disease 2019 (COVID-19) severe-morbidity and mortality
- 36 burdens relative to their more affluent counterparts in Europe, Asia, and North America.
- 37 Methods
- 38 We analysed peripheral blood mononuclear cells (PBMC) samples collected from Kenya and
- 39 Sweden before and during COVID-19. Pre-COVID-19 samples were available for 80 adults
- 40 and 10 infants from Kenya, and 20 adults from Sweden. COVID-19 samples were available
- 41 for 39 Kenyan adults. The samples were analysed for *ex vivo* IFN- $\gamma$  secretion using an
- 42 Enzyme-Linked Immunosorbent (ELISpot) assay following in vitro stimulations with
- 43 overlapping SARS-CoV-2 spike-protein peptides. T-cells expressing IFN-γ, IL-2, TNF-α,
- 44 CD154, and CD107a were assessed following similar stimulations, using intracellular
- 45 cytokine staining (ICS) and multiparameter flow cytometry.
- 46 Results
- 47 55.7% of the Kenyan pre-COVID-19 adults were classified as responders by ELISPOT
- 48 responses to spike-protein peptides, compared with 28% of Swedish pre-COVID-19 adults (p
- 49 = 0.04). The frequencies for SARS-CoV-2 spike-specific TNF- $\alpha$  CD4+, TNF- $\alpha$  CD8+ and
- 50 IFN- $\gamma$  CD8+ T-cell responses, tended to be higher in the Kenyan adults although these
- 51 differences did not reach statistical significance.
- 52 Conclusion
- 53 Pre-COVID-19 T-cell responses could contribute to lower morbidity and mortality associated
- 54 with SARS-CoV-2 infections in SSA relative to Europe, Asia, and North America.
- 55 Keywords: COVID-19, SARS-CoV-2, cross-reactive responses, pre-pandemic, IFN-γ-
- 56 secreting cells, T-cells and Sub-Saharan Africa

# 57 Introduction

58	Most SARS-CoV-2 infections result in either asymptomatic or mild disease, but a small
59	proportion of individuals develop severe COVID-19 requiring hospitalisation, and some of
60	these cases result in death (1). Compared to North America, Asia and Europe, SSA
61	experienced relatively fewer severe cases and fatalities despite many reports of similar
62	SARS-CoV-2-infection rates (2). This paradoxical observation has puzzled many public
63	health experts (3–5). The suggested hypotheses for the reduced burden of severe and fatal
64	COVID-19 in SSA include potential underreporting of cases and deaths, a relatively younger
65	population, warmer climatic conditions, and immune regulation induced from either BCG
66	vaccinations (6-8) or previous exposures to highly inflammatory diseases like malaria (9), or
67	cross protection from a higher level of exposure to other coronaviruses (10–16).
68	There is evidence for cellular and humoral cross-reactivity to SARS-CoV-2 (10–16), and the
69	role for pre-existing hCoV reactive CD4+ T-cell responses in providing SARS-CoV-2 cross
70	protection (17). A high incidence of exposures to hCoVs and other pathogens could have
71	induced pre-COVID-19 cross protective T-cell responses, or could have downregulated
72	inflammation after infections of SSA residents with SARS-CoV-2 (11-16). SARS-CoV-2
73	cross neutralising antibodies are undetectable, even in recent confirmed cases of hCoV (18).
74	However, antigen-specific memory T-cells are more durable and frequently cross-reactive,
75	and may play a key role in the clearance of SARS-CoV-2 infected cells (13,19,20). Recent
76	studies, predominantly conducted in high-income countries (HICs), have reported the
77	presence of pre-COVID-19 cross-reactive T-cell immune responses to SARS-CoV-2 with
78	endemic hCoVs (11-15,20). Studies from SSA countries like Uganda (21,22), Senegal (23),
79	and South Africa (24) have provided some evidence regarding pre-COVID-19 cross-reactive
80	T-cell to SARS-CoV-2 in adults.

81	This study examined <i>ex vivo</i> pre-COVID-19 IFN-γ cellular responses using ELISpot assay
82	and the frequency of functional T-cells, expressing either IFN- $\gamma$ , IL-2, TNF- $\alpha$ , CD154, and
83	CD107a by multiparametric flow cytometry following in vitro stimulation with overlapping
84	SARS-CoV-2 spike peptides. Importantly, we compared results from PBMC samples
85	collected before 2019 from Kenyan and Swedish adults, undertaking standardised assays as a
86	single batch in the same laboratory in Kenya. We further included additional control samples
87	from 10 Kenyan infants (<1 year) and 39 adults COVID-19 patients.
88	
89	Methodology
90	Study design and participants
91	Kenyan pre-COVID-19 blood samples were collected from 80 adults and 10 infants aged
92	below 1 year during an annual malaria surveillance cross-sectional survey conducted in
93	March 2018 in Kilifi. The Swedish pre-COVID-19 blood samples had been collected from 20
94	healthy adult volunteers living in Sweden between March 2012 and June 2019. At the time of
95	pre-COVID-19 sampling, all the individuals had no symptomatic or acute infection. Post-
96	COVID-19 positive control samples were collected from 39 Kenyan adults for studies
97	investigating the kinetics of the immune response to SARS-CoV-2 in COVID-19 patients in
98	Kilifi and Nairobi between 1 <sup>st</sup> August 2020 and 15 <sup>th</sup> February 2022. Blood was separated into
99	plasma and PBMCs and stored at -80°C and liquid nitrogen, respectively, until used for
100	analyses. All the participants consented for their respective samples to be used for both the
101	contemporaneous and future research. This project received ethical approval from the Kenya
102	Medical Research Institute's (KEMRI) Scientific and Ethics Review Unit (SERU) under
103	protocols SERU 3149, 4081 and 4085. Ethical approval for the collection of the Swedish
104	samples was obtained from the regional Ethics Committee in Stockholm, Sweden under
105	protocols 2006/893-31/4 and 2019-03436.

106

## 107 Overlapping SARS-CoV-2 spike peptides and in vitro stimulants for PBMC in the

### 108 ELISpot assay

- 109 Pools of peptides covering the spike region 1 (S1) and spike region 2 (S2) of the SARS-CoV-
- 110 2 spike protein were synthesised by Mimotopes Pty Ltd. Each peptide was 15-mers long and
- 111 overlapped with the next by 10 amino acid residues. A total of 12 mini-pools, P1 to P12 (Pro-
- immune), which corresponded to SARS-CoV-2 spike regions S1 (P1 to P6) and S2 (P7 to
- 113 P12) (25) were used. Two positive controls, phytohemagglutinin-L (PHA-L, Sigma) and anti-
- 114 CD3, were used to induce a mitogenic response and demonstrate viability of lymphocytes and
- 115 T-cells, respectively. A negative control (i.e., no peptide but with the Dimethyl sulfoxide
- 116 [DMSO] carrier) was also included to detect non-specific IFN-γ release. The first 10 samples
- 117 with sufficient cell numbers to test against all 12 peptide pools were included in a preliminary
- analysis to guide peptide pool prioritisation when participant's PBMCs recovered after
- thawing yielded insufficient numbers for testing across all pools. Following this analysis, 4
- 120 peptide pools, 3 and 4 representing S1 region, and 8 and 10 representing S2 region, were
- 121 prioritised when the numbers of PBMCs were inadequate (Figure S1).

122

# 123 ELISpot assay

124 We used an IFN-γ ELISpot assay, which quantifies the frequency of antigen-specific effector

125 cells producing IFN-γ after an overnight co-culture of PBMC with either specific peptides or

- 126 a non-antigen specific positive control (25). Briefly, 96 well ELISpot plates (Millipore, UK)
- 127 were coated with a monoclonal antibody against IFN- $\gamma$  (Mabtech, AB, Sweden) at 10 $\mu$ g/mL
- 128 overnight. 200000 PBMCs per well were plated in triplicates for each individual and plates
- 129 incubated at 37°C in a humidified carbon dioxide (5%) incubator for 16–18 hours of
- 130 stimulation with overlapping peptide pools at 10µg/mL in triplicate wells. After incubation,

131 PBMCs were discarded, the plate washed, and the detector for the secreted IFN- $\gamma$  footprints 132 on the plate membrane, anti- IFN- $\gamma$  biotinylated monoclonal antibody (Mabtech), added at 133  $1\mu g/mL$  and the plate incubated for 2 hours at room temperature. The plate was then washed, 134 and streptavidin alkaline phosphatase (Mabtech) added at 1µg/mL, before another incubation 135 for 1 hour at room temperature. Following washing, the 1-StepTM NBT/BCI (nitro blue 136 tetrazolium/5-bromo-4-chloro-3-phosphatase) substrate (Thermo Scientific) was added, and 137 the plate left in the dark for 7 minutes until the developing spots were clearly visible. The 138 plate was then washed three times using tap water. Following overnight drying, the spots in 139 each well were enumerated with an AID ELISpot Reader (v.4.0). Counts were presented as 140 IFN-γ Spot-Forming Units (SFUs) per million PBMC, which is determined by taking an 141 average of the triplicate wells. Results are reported here as SFUs per million PBMCs after 142 subtracting the background (mean of individual negative wells) from the antigen-specific 143 responses. We summed up the responses from pools P3 and P4 (representing S1) and pools 144 P8 and P10 (representing S2). For the spike region, we combined the aggregated responses 145 from S1 and S2. Individual's assays were considered failed, and their results excluded if the 146 negative control wells had >150 SFUs per million PBMCs, or the positive control wells had 147 <200 SFUs per million PBMCs. An ELISpot assay limit of detection of 10 SFUs per million 148 PBMCs was also applied, and all wells with values <10 SFUs per million PBMCs replaced 149 with a possible minimal result equal to 5 SFUs per million PBMCs. Individuals' IFN- $\gamma$ 150 cellular responses were considered positive, if their SFUs were >71 SFUs per million PBMCs after background subtraction (corresponding to the 25<sup>th</sup> percentile of Kenyan COVID-19 151 152 patients). 153 In total, 79 of 80 pre-COVID-19 Kenyan adults, 10 of 10 of the Kenyan infants, 18 of 20 154 Swedish adults and 37 of 39 post-COVID-19 Kenyan adult patients diagnosed with COVID-155 19 were included in the analysis. Of participants included in the analysis, 78 (99%) pre-

156	COVID-19 Kenyan adults, 3 (30%) Kenyan infants, 5 (28%) Swedish adults and 14 (38%)
157	COVID positive Kenyan patients had all the 12 peptide pools tested (Table S1). Due to the
158	small number of infants, Swedish adults and COVID cases with entire 12 peptide pools
159	tested, subsequent analyses were restricted to the prioritised pools 3 and 4 for S1 responses
160	and pools 8 and 10 for S2 responses, and a summation of pools 3, 4, 8 and 10 for total spike
161	responses (Figure S1).
162	
163	Synthetic peptide pools for intracellular cytokine staining stimulation assay
164	A total of 178 peptides (15–18-mers with a ten amino acid overlap) spanning the entire SARS-
165	CoV-2 spike protein (S: positions 1–178) were synthesised by Mimotopes Pty Ltd and pooled
166	together into one pool for PBMC stimulations. DMSO was used as a negative control and
167	PMA/ionomycin as a positive control.
168	
169	Intracellular cytokine staining and multi-parametric flow cytometry
170	To determine T-cell function, we used ICS and multiparametric flow cytometry to identify
171	and quantify effector T-cells responding to in vitro stimulation by overlapping SARS-CoV-2
172	spike peptides with IL-2, IFN- $\gamma$ and TNF- $\alpha$ cytokine secretion, and upregulation of CD154
173	and CD107a activation makers. Briefly, cryopreserved PBMCs were thawed and rested for 2-
174	4 hours and thereafter plated at $1 \times 10^{6}$ live cells per well for SARS-CoV-2 spike peptide
175	stimulations and the DMSO, and at $0.5 \times 10^{6}$ live cells per well for PMA/ionomycin in 96-
176	well round-bottom plates. SARS-CoV-2 spike peptide stimulation was done at a final
177	concentration of 2 $\mu$ g/mL, PMA at 0.05 $\mu$ g/mL and ionomycin (Sigma) at 0.5 $\mu$ g/mL, and
178	DMSO (Sigma) at 2 $\mu$ g/mL. All the stimulations and controls were done in the presence of
179	the co-stimulatory anti-CD28 and anti-CD49 (1 $\mu$ g/mL, BD Biosciences) antibodies. CD107a
180	BV421 (0.04 $\mu$ g/ml, BD Biosciences) was added to all wells and cells incubated for 1 hour at

181	37°C temperature, 5% CO <sub>2</sub> , 95% humidity for surface staining. Following incubation,
182	Brefeldin A (5 $\mu$ g/mL, MP Biomedicals) was added, and cells incubated for a further 15
183	hours. After washing the cells with 1X PBS, dead cells were labelled using live/dead fixable
184	aqua dye (Invitrogen) for 30 mins at 25°C. The cells were then washed with 1X Perm/Wash
185	before fixation and permeabilisation using Cytofix-Cytoperm for 20 mins at 4°C. Cells were
186	washed three times with 1X Perm/Wash and then stained with APC 'Fire' 750 anti- CD3
187	(Biolegend), PE Dazzle 594-anti- CD4 (Biolegend), PercpCy5.5-anti- CD8 (Biolegend),
188	PECy7- anti-CD154 (Biolegend), APC-anti- IFN-γ (BD Biosciences), PE-anti- IL2
189	(Biolegend) and FITC-anti- TNF- $\alpha$ (BD Biosciences) for 20 mins at 4°C. Cells were washed
190	twice with 1X Perm/Wash and resuspended in 200 $\mu l$ 1X PBS and stored at 4°C in the dark
191	until acquisition. Samples were acquired on a BD LSR Fortessa (BD Biosciences) flow
192	cytometer, and data analysed using FlowJo version 10.10.0 software. Gating strategies used
193	are detailed in (Figure S2). Results are presented as the proportion of IFN- $\gamma$ , IL-2 or TNF- $\alpha$
194	secreting CD4 or CD8 T-cells, or as the proportion of CD154 expressing CD4 T-cells or
195	CD107a expressing CD8 T-cells after subtracting the background (values from negative
196	control wells for each sample). A limit of detection of 0.02% was applied, and all wells with
197	values below 0.02% were replaced with the lowest possible value of 0.01%. Boolean gates
198	were used to examine the frequency of polyfunctional T-cells defined as CD4 or CD8 T-cells
199	co-expressing any of the cytokines IFN- $\gamma$ , TNF- $\alpha$ , IL-2 and surface markers CD154 or
200	CD107a.

201

# 202 Statistical analysis

203 Data management and statistical analysis were performed using GraphPad Prism version

204 10.2.3 (26). IFN-γ SFUs detected by ELISPOT were log-transformed prior to analysis. For

the primary analysis, pairwise comparisons were performed between Kilifi pre-COVID-19

206	adults and Swedish	pre-COVID-19 adults to	assess differences	in IFN-	γ SFUs, as	s well as the
-----	--------------------	------------------------	--------------------	---------	------------	---------------

- 207 proportions of cytokine secreting T-cells and T-cell activation markers in response to SARS-
- 208 CoV-2 spike peptides or its subregions (S1 or S2). A two-sample t-test was used to compare
- 209 IFN- $\gamma$  SFUs as continuous variables, while Fisher's exact test was applied to compare the
- 210 proportions of responders to SARS-CoV-2 spike peptides between Kilifi pre-COVID-19
- adults and Swedish pre-COVID-19 adults. The Mann Whitney test was used for comparisons
- of the proportions of cytokine-secreting T-cells and T-cell activation markers. For the
- 213 secondary analysis, a one-way analysis of variance (ANOVA) with Tukey's multiple
- 214 comparisons test was used to evaluate differences in IFN-γ SFUs across all four study groups.
- 215 The Kruskal Wallis test with Dunn's multiple comparisons test was used to compare the
- 216 proportions of cytokine secreting T-cells and T-cell activation markers in response to SARS-
- 217 CoV-2 spike peptides or subregions across the study groups. A paired t-test was used to
- assess interindividual variability in responses to peptides corresponding to S1 and S2. All
- tests were performed at 5% significance level.

220 Results

#### 221 Participants characteristics

- 222 The median ages of the pre-COVID-19 study participants were 31 years (IQR 24-40 for
- 223 Kenyan adults, 33 years (IQR 31-41) for Swedish adults, and 0.75 years (IQR 0.58-0.83) for
- 224 Kenyan infants. The proportions of male participants were 29% for Kenya adults, 5% for
- Swedish adults and 50% for Kenyan infants. Kenyan COVID-19 patients had a median age of
- 43 years (IQR 34-55), with about one in two being male (Table S2).

227

# **228** IFN-γ responses by ELISpot

- 229 For the S1 region, Kenyan pre-COVID-19 adults tended to have higher IFN-γ responses (with
- a geometric mean of 42 [95% CI 31–56] SFUs per million PBMCs) than Swedish pre-

231	COVID adults	(geometric mean of 22	[95% CI 12–39]	l SFUs pe	er million Pl	BMCs: $p =$	0.05).
				1 ~ - C P P		<b>–</b> – – – – – – – – – – – – – – – – – –	0.00)

- For the S2 region, Kenyan and Swedish pre-COVID-19 adults had similar geometric mean
- responding T-cell numbers at geometric mean of 24 (95% CI: 19–30) and 27 (95% CI: 16–
- 234 45), SFUs per million PBMCs, respectively (p = 0.66; Figure 1a).
- 235 With S1 and S2 regions combined, Kenyan pre-COVID-19 adults had higher responses
- (geometric mean of 70 [95% CI 53–93]) than Swedish pre-COVID-19 adults (49 [95% CI
- 237 29–84]; p = 0.26; Figure 1b). Amongst the Kilifi pre-COVID-19 adults there were higher S1
- responses compared to S2 responses (geometric mean of 42 [95% CI 31–56] vs. 24 [95% CI
- 239 19–30] SFUs per million PBMCs; p < 0.0001) (Figure S3a). For the Swedish pre-COVID-19
- and infants pre-COVID-19, the magnitude of S1 and S2 responses were similar (Figures S3a-
- 241 c).
- 242 We next analysed the proportion of responders within each subgroup. Responders were
- 243 defined as individuals with IFN-γ SFUs responses exceeding 71 SFU per million PBMCs
- after background subtraction, corresponding to the 25th percentile of Kenyan COVID-19
- patients. Notably, 55.7% of the Kenyan pre-COVID-19 adults were classified as responders,
- which was significantly higher than 28% of Swedish pre-COVID-19 adults (p = 0.04) in
- response to SARS-CoV-2 spike peptides. Among Kenyan pre-COVID-19 infants, 40% were
- responders. As expected, a large proportion, 75.7% of the COVID-19 positive individuals
- 249 were classified as responders (Figure 1c).
- 250

# 251 Cross reactive cytokine responses to SARS-CoV-2 peptides by ICS

- **252** To establish whether the IFN-γ responses observed by ELISpot were from memory T-cells
- and whether other cytokines were secreted, we incorporated ICS assay followed by
- 254 multiparametric flow cytometry. Our data show that both CD4+ and CD8+ T-cells from the
- 255 different groups produced IFN- $\gamma$ , TNF- $\alpha$  and IL-2 after incubation with overlapping SARS-

256	CoV-2 spike peptides. CD4+ T-cells also upregulated CD154 an activation marker. Kenyan
257	pre-COVID-19 adults exhibited higher cytokines levels for IFN- $\gamma$ and TNF- $\alpha$ responses,
258	though not statistically significant (Figure 2). For the IFN-γ CD8+ T-cell responses, Kenyan
259	pre-COVID-19 adults had a higher median of 0.06% (IQR 0.01-0.54%) compared to
260	Swedish pre-COVID-19 adults (median: 0.01% [IQR 0.01–0.4%]; $p = 0.54$ ). The TNF- $\alpha$
261	CD4+ T-cell responses were higher in Kenyan pre-COVID-19 adults (median: 0.03% [IQR
262	0.01-0.095%]) than Swedish pre-COVID-19 adults (median: 0.015% [IQR 0.01-0.055%]; p
263	= 0.39). Similarly, TNF- $\alpha$ CD8+ T-cell responses were elevated in Kenyan pre-COVID-19
264	adults (median: 0.06% [IQR 0.01-0.17%]) compared to Swedish pre-COVID-19 adults
265	(median: 0.03% [IQR 0.01–0.05%]; p = 0.13) (Figure 2b, c–d). The Kenyan COVID-19
266	patients had significantly higher TNF- $\alpha$ CD4+ T-cells levels (median: 0.26% [IQR 0.11–
267	0.73%]) compared to Kenyan pre-COVID-19 adults, (median: 0.03% [IQR 0.01-0.095%];
268	p=0.01), Kenyan pre-COVID-19 infants (median: 0.02% [IQR 0.01-0.04%]; p= 0.007) and
269	Swedish pre-COVID-19 adults (median: 0.015% [IQR 0.01–0.055%]; p= 0.005) (Figure 2c).
270	IL-2 CD4+ T-cell frequencies were also higher in Kenyan COVID-19 patients (median:
271	0.09% [IQR 0.015-0.515%]) compared to Kenyan pre-COVID-19 adults (median: 0.01%
272	[IQR 0.01–0.025%]; p= 0.02) and Swedish pre-COVID-19 adults (median: 0.01% [IQR
273	0.01–0.01%]; p= 0.004) (Figure 2e).
274	Our analysis of the number of functional markers co-expressed by these T-cells showed that
275	only a small proportion of individuals showed polyfunctionality prior to COVID-19.

276 Individuals analysed post COVID-19 had better CD4 and CD8 T-cell polyfunctionality.

277 Compared to Swedish pre-COVID-19 adults, a higher proportion of Kenyan pre-COVID-19

- adults had polyfunctional CD4+ and CD8+ T-cells (Figure S4a, b). Collectively, these data
- suggest that the pre-COVID-19 CD4+ and CD8+T-cells from Swedish adults were less
- **280** primed to secrete TNF- $\alpha$  and IFN- $\gamma$  compared to those of the Kenyan pre-COVID-19 adults.

# 281 Discussion

282	We compared the frequencies and prevalence of SARS-CoV-2 cross-reactive T-cell
283	responses by measuring IFN- $\gamma$ responses by ELISPOT and phenotypic and functional
284	characterization by flow cytometry in pre-COVID-19 PBMC collected in Kenya, and in
285	Sweden. We observed higher S1 specific and full spike frequencies, and a greater prevalence,
286	of pre-pandemic SARS-CoV-2 spike peptide specific cross-reactive IFN- $\gamma$ secreting cells
287	measured by an ELISpot assay in Kenyan adults, compared to Swedish adults. Overall, these
288	data suggest that Kenyan pre-COVID-19 adults had higher IFN- $\gamma$ SFU responses to the S1
289	and spike regions but similar S2 responses compared to Swedish pre-COVID-19 adults. A
290	larger proportion of Kenyan pre-COVID-19 adults also responded to SARS-CoV-2 spike
291	peptides. Responses to S1-specific S2-specific, and to the full spike region increased
292	following contact with COVID-19. These findings suggest a greater pre-pandemic exposure
293	to S1-like epitopes in Kenya contributing to SARS-CoV-2 cross-reactive T-cell responses
294	compared to Sweden.
294 295	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN- $\gamma$ secreting cells included
294 295 296	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan
294 295 296 297	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic
294 295 296 297 298	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or
294 295 296 297 298 299	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT
294 295 296 297 298 299 300	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT assay is more sensitive than the ICS assay we used, and therefore the power to detect
294 295 296 297 298 299 300 301	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT assay is more sensitive than the ICS assay we used, and therefore the power to detect differences between populations is more limited in the ICS work.
294 295 296 297 298 299 300 301 302	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT assay is more sensitive than the ICS assay we used, and therefore the power to detect differences between populations is more limited in the ICS work. The higher frequencies and prevalence of IFN-γ secreting cells among the Kenyan pre-
294 295 296 297 298 299 300 301 302 303	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT assay is more sensitive than the ICS assay we used, and therefore the power to detect differences between populations is more limited in the ICS work. The higher frequencies and prevalence of IFN-γ secreting cells among the Kenyan pre- pandemic adult-PBMCs compared to their Swedish counterparts is consistent with higher
294 295 296 297 298 299 300 301 302 303 304	compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT assay is more sensitive than the ICS assay we used, and therefore the power to detect differences between populations is more limited in the ICS work. The higher frequencies and prevalence of IFN-γ secreting cells among the Kenyan pre- pandemic adult-PBMCs compared to their Swedish counterparts is consistent with higher

Page 12 of 20

306	prevalence	of severe	COVID-	19 and	deaths in	Kenva	a relative to	European	countries like
		01 00 . 010							•••••••••

- 307 Sweden. This idea is consistent with previous observations of protection from severe
- 308 COVID-19 by recent exposures to endemic hCoVs (27). Furthermore, mechanistic studies in
- 309 mice demonstrated that hCoV-specific, SARS-CoV-2–cross-reactive T -cells contribute to
- **310** SARS-CoV-2 immune responses upon infection and vaccination (17).
- 311 There is little evidence for a role for cross-reactive neutralising antibodies as these are rare,
- 312 even where there is PCR evidence for recent hCoV infection (18). The mechanism by which
- 313 SARS-CoV-2 cross reactive CD4+ T-cells lower COVID-19 severity may include various
- 314 mechanisms such as the direct killing of virus infected cells, or through their ability to offer
- 315 CD8 T cells help and protecting against infection, or both, thus reducing viral loads (28–30).
- 316 Alternatively (or in addition), SARS-CoV-2 cross reactive memory CD4+ T-cells may
- 317 provide the necessary costimulatory molecules for helping rapid and amnestic production of
- **318** protective antibodies (17).
- 319 This study has a few limitations. First, for the ICS assays, we only had access to PBMC from
- 320 21 Kenyan pre-covid-19 adults,10 Kenyan pre-covid-19 infants, 10 Swedish pre-covid-19
- 321 adults and 9 Kenyan covid-19 adults, which reduced the statistical power of comparing
- 322 responses among the groups. Second, we were only able to use spike peptides to stimulate
- 323 PBMCs as the numbers of cells was limiting, it would have been more comprehensive to
- 324 include other SARS-CoV-2 proteins.
- 325

## 326 Conclusion

- 327 We report higher frequencies and prevalence of pre-COVID-19 SARS-CoV-2 spike cross-
- 328 reactive IFN-  $\gamma$  secreting cells, some of which include CD8+ T -cells, among Kenyan
- 329 compared to Swedish adults. This raises the possibility that higher levels of cross-protective
- 330 cellular responses in SSA could explain, at least in part, why there was less severe morbidity

<b>33</b> and mortanty on the continent relative to Europe, Asia and north America. None	331	and mortality on	n the continent	relative to I	Europe, Asia	a and North	America.	Nonetheles
--	-----	------------------	-----------------	---------------	--------------	-------------	----------	------------

- 332 subsequent studies including relatively higher samples sizes of pre-COVID-19 PBMC from
- 333 SSA and a few more countries from Europe and/or America are required to confirm these
- 334 findings and extend the research into investigating the actual mechanism of the SARS-CoV-2
- 335 cross-protection. Importantly, such studies will provide new insights on how to develop novel
- 336 cross-protective vaccines against similar pathogens, like coronaviruses.
- 337

#### 338 Acknowledgments

- 339 We thank the field workers, laboratory staff and healthcare workers involved in the blood
- 340 sampling. We appreciate all the study participants.
- 341

# **342 Competing Interests**

- 343 No competing interests to declare.
- 344

# 345 Funding Statement

- 346 This study/project is funded by the EDCTP2 Programme (grant number RIA2020EF-3042)
- 347 which is supported by the European Union, and the Swedish International Development
- **348** Cooperation Agency.
- 349 SJD is supported by an NIHR Global Health Research Professorship (NIHR300791).
- 350
- 351

#### 352 References

- 353 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
- 354 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases

355 From th	le Chinese	Center for	Disease	Control and	Prevention.	JAMA.	2020 Ap
-------------	------------	------------	---------	-------------	-------------	-------	---------

- **356** 7;323(13):1239–42.
- 2. Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al.
- 358 COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past
- trends and future patterns. Lancet Glob Health. 2022 Aug;10(8):e1099–114.
- 360 3. Osayomi T, Adeleke R, Akpoterai LE, Fatayo OC, Ayanda JT, Moyin-Jesu J, et al. A
- 361 Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-
- 362 Vaccine Hypothesis to the Test. Earth Syst Environ. 2021 Sep 1;5(3):799–810.
- 363 4. Ghosh D, Bernstein JA, Mersha TB. COVID-19 pandemic: The African paradox. J Glob
  364 Health. 10(2):020348.
- 365 5. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. Science.
  366 2021 Jan;371(6524):27–8.
- 367 6. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al. What
- 368 Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation
- of the SARS-CoV-2 Virus? Int J Environ Res Public Health. 2021 Aug 16;18(16):8638.
- 370 7. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe

371 coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020 Jul

- **372** 28;117(30):17720–6.
- 373 8. Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J. The BCG
- 374 Vaccine for COVID-19: First Verdict and Future Directions. Front Immunol. 2021 Mar
  375 8;12:632478.
- 376 9. Tapela K, Prah DA, Tetteh B, Nuokpem F, Dosoo D, Coker A, et al. Cellular immune
- 377 response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic
- 378 malaria. Cell Reports. 2024 Aug 27;43(8):114533.

- 379 10. Ashworth J, Mathie D, Scott F, Mahendran Y, Woolhouse M, Stoevesandt O, et al.
- 380 Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples
- from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-
- sectional study. The Lancet Microbe. 2023 Apr 1;4(4):e215–27.
- 383 11. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-
- 384 reactive T -cells in healthy donors and patients with COVID-19. Nature. 2020 Nov
- **385** 12;587(7833):270–4.
- 386 12. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-
- 387 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
- 388 Nature. 2020 Aug;584(7821):457–62.
- 389 13. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets
- 390of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
- and Unexposed Individuals. Cell. 2020 Jun 25;181(7):1489-1501.e15.
- 392 14. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.
- 393 Phenotype and kinetics of SARS-CoV-2–specific T -cells in COVID-19 patients with
- acute respiratory distress syndrome. Science Immunology. 2020 Jun 26;5(48):eabd2071.
- 395 15. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-
- reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020 Oct
- **397** 2;370(6512):89–94.
- 398 16. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021
- **399** Feb;184(4):861–80.
- 400 17. Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, et al. Cross-reactive CD4+
- 401 T -cells enhance SARS-CoV-2 immune responses upon infection and vaccination.
- 402 Science. 2021 Oct 8;374(6564):eabh1823.

- 403 18. Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatziioannou T, et al. Absence
- 404 of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in
- 405 Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. Clin
- 406 Infect Dis. 2021 Sep 7;73(5):e1208–11.
- 407 19. de Candia P, Prattichizzo F, Garavelli S, Matarese G. T -cells: Warriors of SARS-CoV-2
- 408 Infection. Trends Immunol. 2021 Jan;42(1):18–30.
- 409 20. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al.
- 410 Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
- 411 COVID-19. Cell. 2020 Oct 1;183(1):158-168.e14.
- 412 21. Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, et al.
- 413 Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and
- 414 CD8+ T-cell responses: A pilot study. PLOS Global Public Health. 2023 Aug
- 415 16;3(8):e0001566.
- 416 22. Nantambi H, Sembera J, Ankunda V, Ssali I, Kalyebi AW, Oluka GK, et al. Pre-
- 417 pandemic SARS-CoV-2-specific IFN- $\gamma$  and antibody responses were low in Ugandan
- 418 samples and significantly reduced in HIV-positive specimens. Front Immunol [Internet].
- 419 2023 Apr 19 [cited 2024 Sep 23];14. Available from:
- 420 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1148877/
  421 full
- 422 23. Herrera BB, Chaplin B, MBoup S, Abdullahi A, He M, Fisher SM, et al. West African
- 423 pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2
- 424 [Internet]. medRxiv; 2024 [cited 2024 Sep 23]. p. 2024.05.21.24307417. Available from:
- 425 https://www.medrxiv.org/content/10.1101/2024.05.21.24307417v1
- 426 24. Nunes MC, Johnson MJ, Kwatra G, Weinberg A, Madhi SA. T-cell responses to SARS-
- 427 CoV-2 in unexposed South African women. Gates Open Res. 2022 Jul 13;5:150.

- 428 25. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays
- 429 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral
- 430 responses. Nat Commun. 2021 Apr 6;12(1):2055.
- 431 26. Graph pad prism programming team. Graph pad Prism, Boston, Massachusetts, USA.
- 432 2023 [cited 2024 Apr 11]. Prism GraphPad. Available from:
- 433 https://www.graphpad.com/features
- 434 27. Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic
- 435 coronavirus infection is associated with less-severe COVID-19. J Clin Invest [Internet].
- 436 2021 Jan 4 [cited 2024 Oct 30];131(1). Available from:
- 437 https://www.jci.org/articles/view/143380
- 438 28. Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022
- **439** Feb;23(2):186–93.
- 440 29. Wyllie D, Jones HE, Mulchandani R, Trickey A, Taylor-Phillips S, Brooks T, et al.
- 441 SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated
- 442 with protection from COVID-19: A prospective cohort study in keyworkers [Internet].
- 443 medRxiv; 2021 [cited 2024 Sep 20]. p. 2020.11.02.20222778. Available from:
- 444 https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v2
- 445 30. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive
- 446 memory T -cells associate with protection against SARS-CoV-2 infection in COVID-19
- 447 contacts. Nat Commun. 2022 Jan 10;13(1):80.
- 448
- 449 Figures
- 450 Figure 1. Comparison of the frequencies of IFN-gamma secreting cell responses to
- 451 SARS-CoV-2 Spike regions 1 and 2 among study groups. a frequencies of Spike regions 1
- 452 and 2 separately, **b** aggregated frequencies of Spike regions 1 and 2, **c** Responders (Cut off

- 453 for responders is 25<sup>th</sup> percentile of Spike in CoV-adults). Comparisons done using t-test,
- 454 ordinary one-way ANOVA with Tukey's multiple comparisons test and Fisher's exact test.



455 Black line shows Geometric mean.

- 456
- 457



459 SARS-CoV-2 Spike protein. i) Cytokine responses levels of a IFN-γ in CD4+ T cells, b

460 IFN-γ in CD8+ T cells, c TNF in CD4+ T cells, d TNF in CD8+ T cells, e IL-2 in CD4+ T

461 cells, f IL-2 in CD8+ T cells ii) Surface markers g CD154 on activated CD4+ T cells h

462 CD107a on CD8+ T cells.

463 Number of participants for: Kilifi pre-covid adults = 21, Kilifi pre-covid infants = 11, Sweden

464 pre-covid adults = 10, Covid-19 adults = 9. Black line shows median.



465

466